TrialPath

Find a study

Studies of GLP-1, incretin, and related peptide medications for weight and metabolic health.

Match me to a study

89 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicPeptide & GLP-1Mental healthLungs & breathingHeart & circulationKidneyBrain & memoryBlood disordersImmune & autoimmuneSkin

81 studies on the map

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study — Digestive Health Specialists, DothanEfficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes — Kailera Clinical Site, CullmanA Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO) — Medical Dermatology Specialists, PhoenixMirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight — Digestive Health Specialists, DothanA Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes — MFA Clinical Research, TuscaloosaA Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes — Pinnacle Research Group, AnnistonA Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight — The Institute for Liver Health II dba Arizona Clinical Trials - Mesa, ChandlerA Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight — Neighborhood Healthcare, EscondidoEfficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight — AMR Clinical, MobileEfficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes — Kailera Clinical Site, GlendaleEfficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes — Kailera Clinical Site, AnnistonA Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin — Birmingham Clinical Research, BirminghamA Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight — Cullman Clinical Trials, CullmanA Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes — Lakeview Clinical Research, GuntersvilleA Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes — Birmingham Clinical Research, BirminghamEfficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH) — Cahaba Research, Inc., PelhamA Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain — Arizona Research Center, Inc., PhoenixA Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain — MD First Research - Chandler, ChandlerA Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA) — AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Avondale, AvondaleAMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain — Neighborhood Healthcare, EscondidoAMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight — South Broward Research LLC, MiramarAMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea — Dignity Health, Mercy Gilbert, GilbertAMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss — Pinnacle Research Group LLC, AnnistonA Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight — Uni of Alabama at Birmingham, BirminghamA Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes — Prime Medical Group, LLC dba Gilbert Center for Family Medicine, LLC, GilbertProof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss — DM Clinical Research - Phoenix, PhoenixAMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea — Artemis Insitute for Clin Res, San DiegoAMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight — Univ of Alabama Birmingham, BirminghamMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy — Valley Clinical Trials, NorthridgeA Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2) — Children's Hospital Los Angeles, Los AngelesA Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight — Arizona Clinical Trials, ChandlerMaridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity — University of Alabama Saint Vincent's Birmingham, BirminghamEvaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events — Diablo Clinical Research, Inc., Walnut CreekEvaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity — Alliance For Multispecialty Research - Daphne, DaphneA Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity — Advanced Cardiovascular, LLC, Alexander CityEffect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity — Fortrea Clinical Research Unit - Daytona Beach, Daytona BeachTirzepatide in PWS, HO and GNSO — Children's Minnesota, Saint PaulA Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet — Advent Health-Res Inst, OrlandoSemaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation — The University of Arizona College of Medicine- Phoenix, PhoenixTargeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis — Johns Hopkins University, BaltimoreMechanisms of Semaglutide Therapy in Heart Failure Patients — Greenstone Biosciences, Palo AltoWeight Loss in Adults Using Semaglutide (Real-world Study) — Novo Nordisk Investigational Site, SeattleSemaglutide for Post-Smoking Cessation Weight Management — The University of Texas at Austin, AustinIncreased Dietary Protein Intake During GLP-1 Medication Use (in Middle-aged Women With Overweight/Obesity) — Dell Pediatric Research Center, AustinDietary Insights and Nutrition Experiences in Adults on GLP-1 Therapy - A Study on Diet Quality Changes in Adults on GLP-1 Therapy — University South Carolina, ColumbiaMAINTAIN (Mucosal AblatIoN Therapy After INcretins) — True You Weight Loss, CaryTIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation — Cleveland Clinic, ClevelandComparison of Body Composition Changes With Weight Loss Interventions — Vanderbilt University Medical Center, NashvillePhysiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents — Childrens Hospital Colorado, AuroraFeasibility of Semaglutide in Advanced Lung Disease — University of Pennsylvania Perelman School of Medicine, PhiladelphiaEffect of Tirzepatide on Markers of MASLD in Patients With Obesity — University of New Mexico Health Sciences Center, AlbuquerqueThe Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity — Mayo Clinic in Florida, JacksonvilleTirzepatide in Obesity-Driven Endometrial Cancer — Lineberger Comprehensive Cancer Center, Chapel HillMitigation of Cardiovascular Disease Risks in Children With Extreme Obesity — University of Kentucky, LexingtonBody Composition and Exercise to Prevent Muscle Loss With GLP1 Agonist Treatment — Diabetes Research Center, BostonIncretin Microdosing for Cardiometabolic Health in People With HIV — The University of Texas Health Science Center at Houston, HoustonTirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity — Clinical and Translational Research Unit, Palo AltoBrown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects. — UCLA Health, Los AngelesSemaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants — Celerion Clinical Research, TempeObesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment — Yale Pediatric Diabetes Center, Adult and Children's Progam, New Haven2024 Tirzepatide-Bariatric Surgery — University of Kentucky, LexingtonGlucagon-Like Peptide-1 Receptor Agonist in ADPKD — University of Colorado - Anschutz Medical Campus, AuroraEffect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity — Massachusetts General Hospital, BostonThe Effects of Strength Training on Muscle Mass and Mental Health in Adults Taking Obesity Medication — Physical Activity Research Center, University of Pittsburgh, PittsburghRole of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome — University of Colorado Anschutz/Children's Hospital Colorado Aurora, AuroraEfficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder — Johns Hopkins University, BaltimoreA Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults — Frontage Clinical Services, Inc., SecaucusImpact GLP-1 Agonists Following Bariatric — University of Missouri Hospital, ColumbiaTirzepatide for Alcohol Use Disorder — Keck School of Medicine, University of Southern California, Los AngelesBone Metabolism in 12-21 Year Olds Undergoing Glucagon Like Peptide (GLP)-1 Receptor Agonist Therapy — University of Virginia Medical Center, CharlottesvilleDietary Insights and Nutritional Education in Adults on GLP-1 Therapy — University South Carolina, ColumbiaRandomized Control Trial of Sleeve Gastrectomy With Tirzepatide in Maximizing Weight Loss — Rush University Medical Center, ChicagoResistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity — St. Jude Children's Research Hospital, MemphisTirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors — Weill Cornell Medicine, New YorkPeople With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists — Northwestern Memorial Hospital, ChicagoExamination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) — Altasciences Clinical LA, Inc., CypressEffects of Glucagon-like Peptide-1 (GLP-1) Agonist in Neuro-reproductive Function in Obese Adolescent Females With Polycystic Ovary Syndrome (PCOS) — Nemours Children's Clinic, JacksonvilleRole of Caveolin 1 (CAV-1) Deficiency in Response to Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Treatment — Brigham and Women's Hospital, BostonGlucagon-like Peptide 1 (GLP-1) Receptor Agonist Therapy and Exercise Training in People With Obesity — Washington University School of Medicine, St LouisEffects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults — University of Texas Health Science Center at San Antonio, San AntonioGLP-1R Actions on Muscle and the Skeleton — Pennington Biomedical Research Center, Baton Rouge